Literature DB >> 27982218

Management of necrotizing scleritis after pterygium surgery with rituximab.

Tania Sales de Alencar Fidelix1, Luis Antonio Vieira1, Virginia Fernandes Moca Trevisani1.   

Abstract

The authors present a case of necrotizing scleritis after pterygium excision successfully treated with rituximab after attempts with high doses of corticosteroids and immunosuppressive drugs. A literature review revealed case reports and a phase I/II dose-ranging randomized clinical trial using rituximab for necrotizing scleritis with or without association with autoimmune disease. This is the only case report on rituximab treatment for necrotizing scleritis after pterygium surgery. In cases with refractoriness to immunosuppressive drugs, a CD20 antibody can be used.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27982218     DOI: 10.5935/0004-2749.20160097

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  3 in total

1.  Commentary: Rituximab in scleritis.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

Review 2.  Management of noninfectious scleritis.

Authors:  Ahmad Abdel-Aty; Akash Gupta; Lucian Del Priore; Ninani Kombo
Journal:  Ther Adv Ophthalmol       Date:  2022-01-21

Review 3.  Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.

Authors:  Jurgen Sota; Matteo-Maria Girolamo; Bruno Frediani; Gian Marco Tosi; Luca Cantarini; Claudia Fabiani
Journal:  Ophthalmol Ther       Date:  2021-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.